Skip to main content

Table 1 Demographic and clinical characteristics of episodes of new allopurinol users (baseline with no ventricular arrhythmias; baseline was 365 days)

From: Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data

  All new allopurinol use episodes Allopurinol new use episodesa associated with versus without ventricular arrhythmias (VA) during the follow-up P value
  VA No VA  
Total, N (episodes) 28,755 2538 26,217  
Age, mean (SD) 76.6 (7.4) 77.2 (7.3) 76.5 (7.5) < 0.0001
Sex, N (%)     < 0.0001
 Male 14,074 (48.9%) 1369 (53.9%) 12,705 (48.5%)  
 Female 14,681 (51.1%) 1169 (46.1%) 13,512 (51.5%)  
Race/Ethnicity, N (%)     < 0.0001
 White 22,693 (78.9%) 1976 (77.9%) 20,717 (79.0%)  
 Black 3510 (12.2%) 382 (15.1%) 3128 (11.9%)  
 Hispanic 606 (2.1%) 49 (1.9%) 557 (2.1%)  
 Asian 1268 (4.4%) 89 (3.5%) 1179 (4.5%)  
 Native American 97 (0.3%) 7 (0.3%) 90 (0.3%)  
 Other/unknown 581 (2.0%) 35 (1.4%) 546 (2.1%)  
Region, N (%)     0.03
 Northeast 4607 (16.0%) 460 (18.1%) 4147 (15.8%)  
 Midwest 7315 (25.4%) 626 (24.7%) 6689 (25.5%)  
 South 11,563 (40.2%) 1003 (39.5%) 10,560 (40.3%)  
 West 5270 (18.3%) 449 (8.5%) 4821 (18.4%)  
Charlson–Romano comorbidity score 3.65 (3.25) 4.79 (3.40) 3.54 (3.21) < 0.0001
  1. SD, standard deviation
  2. aAll data are at episode level
  3. Significant P values are in bold